Skip to main content
. 2020 Mar 12;106(5):1262–1277. doi: 10.3324/haematol.2019.233445

Figure 6.

Figure 6.

CUDC-907 downregulates c-Myc expression enhancing the antileukemic activity of venetoclax in acute myeloid leukemia cells. (A) Acute myeloid leukemia (AML) cells were treated, as indicated, for 16 or 24 hours and western blot analysis of whole cell lysates are shown together with the fold changes for the densitometry measurements, normalized to β-actin and then compared to vehicle control. (B) AML cells were treated as in panel A. Total RNA was isolated and c-Myc transcripts were measured by real-time RT-PCR. **P<0.001 compared to control. (C) U937 cells were infected with Precision LentiORF c-Myc or RFP control lentivirus particles overnight, then washed and incubated for 24 hours. Whole cell lysates from one aliquot of cells were subjected to western blotting (top panel). Densitometry measurements were normalized to b-actin; fold changes compared to RFP control are shown. The other aliquot of cells were treated with vehicle control, venetoclax, CUDC- 907, or in combination for 24 hours. Flow cytometry analysis results of Annexin V-FITC/PI staining are shown as mean Annexin V positive ± standard error of the mean (SEM) (bottom panel). ***P<0.001. (D) U937 cells were treated with vehicle control, 10058-F4, venetoclax, or in combination for 24 hours. Representative western blots of c-Myc and b-actin are shown (top panel). Densitometry measurements of c-Myc were normalized to β-actin; fold changes compared to vehicle control are shown. Flow cytometry analysis results of Annexin V-FITC/PI staining are shown as mean Annexin V positive ± SEM (bottom panel). ***P<0.001. (E) U937 cells were treated as in panel D and then subjected to alkaline comet assay. Representative images are shown (left panel). Results are shown as median percent DNA in tail from three replicate gels ± SEM (right panel). (F) Proposed mechanisms of action of venetoclax in combination with CUDC-907. CUDC-907 treatment increases Bim and decreases Mcl-1, but Bcl-2 sequesters Bim, which opposes apoptosis. Venetoclax treatment reduces Bim binding to Bcl-2, tipping the balance towards more “free” Bim, inducing apoptosis. CUDC-907 downregulates CHK1, Wee1, RRM1, and c-Myc, inducing DNA damage, while venetoclax prevents DNA repair, leading to accumulation of DNA damage and more cell death.